Baxter Injects $625m In ‘Foundational Asset’ Claris

Baxter has snapped up India’s Claris Injectables, accelerating efforts to become a global leader in generic injectables. The deal also puts the spotlight back on the significant M&A appetite in the niche injectables segment and the scarcity premiums that such assets can command.

Deal street swung back into action in India ahead of the holiday season with Baxter International Inc. acquiring Claris Lifesciences Ltd.’s injectables arm, Claris Injectables Ltd, for about $625m.

The transaction fast-tracks the US firm’s quest to emerge as a global leader in the generic injectables segment and also ends long-running speculation around an imminent sale of Claris’ injectables...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.